… This review discusses the role of PHD inhibitors in the treatment of anemia associated …
Prolyl hydroxylase inhibitors decrease hepcidin and thus reduce the functional iron deficiency in …

… ) by inhibiting prolyl hydroxylase (… treatment of anemia in patients with CKD, 6 this review
focuses on the mechanism of action and results of phase 1 and 2 studies of 4 HIF-PH inhibitors …

… of the potential for HIF–prolyl hydroxylase inhibitors to increase VEGF levels through
induction of the VEGF gene. Furthermore, HIF–prolyl hydroxylases may indirectly regulate VEGF …

… developed for the treatment of renal anaemia. These molecules inhibit prolyl hydroxylase
domain-… Currently, renal anaemia is treated with recombinant human erythropoietin or related …

… -inducible factor–prolyl hydroxylase domain inhibitors (HIF-… clinical development for the
treatment of anemia of chronic kidney … HIF-PHI trials in patients with anemia of CKD, discusses …

… increase with gene therapy and blockade of HIF prolyl hydroxylases through interference …
dependent on specificity of therapy for particular isoforms of HIF or HIF prolyl hydroxylases. …

… Overview of the regulation of hypoxia-inducible factor (HIF)-2α and therapeutic mechanism
of prolyl hydroxylase domain (PHD) inhibitors for the treatment of renal anemia. (a) Under …

… safety concerns call for safer, effective, and accessible treatment for CKD anemia ( 21 ). …
factor prolyl hydroxylase inhibitor (HIF-PHI). Transient inhibition of prolyl hydroxylase by hypoxia …

… Prolyl hydroxylase inhibitors are known to increase the … a new therapeutic approach for
the treatment of anemia [5] [13]. … the only major treatment for anemia of CKD today. However, …

… Although ESAs are well-established and highly efficacious treatment, clinical trials … inducible
factor-prolyl hydroxylase inhibitors (HIF-PHIs) are such novel agents to treat anemia in CKD. …